SEC Filing Document

Company: Berto Acquisition Corp. II
Ticker: GUAC
CIK: 2081515
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-04-27
Accession Number: 0001829126-26-003952
Exchange: 
SIC Code: 6770
SIC Description: Blank Checks
URL: https://www.sec.gov/Archives/edgar/data/2081515/000182912626003952/bertoacquisition2_s1.htm

Chunk 56 of 128
Word Count: 1488
Character Count: 9982

Document Content:

officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any of our shares or other securities, whether by transfer, sale, operation of law or otherwise, shall be deemed to have notice of and have irrevocably agreed and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies’ charter documents has been challenged in legal proceedings. It is possible that a court could find this type of provisions to be inapplicable or unenforceable, and if a court were to find this provision in our articles to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could have adverse effect on our business and financial performance.

Recent increases in inflation in the United States and elsewhere could make it more difficult for us to complete our initial business combination.

Recent increases in inflation in the United States and elsewhere may lead to increased price volatility for publicly traded securities, including ours, or other national, regional or international economic disruptions, any of which could make it more difficult for us to complete our initial business combination.

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Some of the statements contained in this prospectus may constitute “forward-looking statements” for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward- looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements about:

●	our ability to select an appropriate target business or businesses;

●	our ability to complete our initial business combination;

●	our expectations around the performance of the prospective target business or businesses;

●	our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;

●	our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination;

●	our potential ability to obtain additional financing to complete our initial business combination;

●	our pool of prospective target businesses;

●	our ability to consummate an initial business combination due to uncertainty and adverse impacts resulting from events outside of our control, such as increased geopolitical events like the conflicts in Ukraine, Israel and Gaza and Iran and economic impacts such as inflation and rising interest rates;

●	the ability of our officers and directors to generate a number of potential business combination opportunities;

●	our public securities’ potential liquidity and trading;

●	the lack of a market for our securities;

●	the use of proceeds not held in the trust account or available to us from interest income on the trust account balance;

●	the trust account not being subject to claims of third parties; or

●	our financial performance following this offering.

Table of Contents

The forward-looking statements contained in this prospectus are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors”. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

In addition, statements that contain “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this prospectus. Although we believe that this information provides a reasonable basis for these statements, this information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.

Table of Contents

USE OF PROCEEDS

We are offering 25,000,000 units at an offering price of $10.00 per unit. We estimate that the net proceeds of this offering together with the funds we will receive from the sale of the private placement warrants will be used as set forth in the following table.

Without Over-allotment Option Over-allotment Option Exercised

Gross proceeds

Gross proceeds from units offered to public (1) $	250,000,000 $	287,500,000

Gross proceeds from private placement warrants offered in the private placement $	3,500,000 $	3,500,000

Total gross proceeds $	253,500,000 $	291,000,000

Estimated offering expenses (2)

Underwriting commissions (0.4% of gross proceeds from units offered to public, excluding units sold pursuant to the over-allotment option and excluding deferred portion) (3) 1,000,000 1,000,000

Consulting fee (4) $	500,000 $	500,000

Legal fees and expenses 400,000 400,000

Printing and engraving expenses 15,000 15,000

Accounting fees and expenses 66,000 66,000

SEC Expenses 55,500 55,500

FINRA Expenses 43,625 43,625

Nasdaq listing and filing fees 81,000 81,000

Travel and road show expenses 60,000 60,000

Miscellaneous 49,375 49,375

Total offering expenses (other than underwriting commissions) $	1,270,000 $	1,270,000

Proceeds after estimated offering expenses $	251,230,000 $	288,730,000

Held in trust account (3) $	250,000,000 $	287,500,000

% of public offering size 100	% 100	%

Not held in trust account $	1,230,000 $	1,230,000

The following table shows the use of the approximately $1,230,000 net proceeds not held in the trust account(5)

Amount % of Total

Accounting, due diligence, travel, and other expenses in connection with any business combination $	200,000 16.3	%

Legal and accounting fees related to regulatory reporting obligations 300,000 24.4	%

Nasdaq continued listing fees 85,000 6.9	%

Payment for office space, secretarial and administrative services (6) 360,000 29.3	%

D&O insurance 200,000 16.3	%

Working capital to cover miscellaneous expenses 85,000 6.9	%

Total $	1,230,000 100.0	%

(1)	Includes amounts payable to public shareholders who properly redeem their shares in connection with our successful completion of our initial business combination.

(2)	A portion of the offering expenses have been paid from the proceeds of loans from our sponsor of up to $300,000 as described in this prospectus. These loans will be repaid upon completion of this offering out of the $1,270,000 of offering proceeds that has been allocated for the payment of offering expenses other than underwriting commissions. In the event that offering expenses are less than set forth in this table, any such amounts will be used for post-closing working capital expenses. As of December 31, 2025, we had borrowed approximately $16,000 under the promissory note.

Table of Contents

(3)	The underwriters have agreed to defer underwriting commissions equal to $9,750,000 of the gross proceeds of this offering, or up to $11,212,500 in the aggregate, payable to the underwriters in this offering upon completion of our initial business combination. Such fees will be paid to the underwriters from the remaining cash held in the Company’s trust account at the closing of the initial business combination. However, such deferred commissions shall be due solely from amounts remaining in the trust account following all properly submitted shareholder redemptions in connection with the consummation of our initial business combination and less any funds sourced by initial shareholders or any cash remaining in the trust pursuant to structured agreements such as forward purchase agreements, non-redemption agreements, any agreements or arrangements alike, or any other incentivization provided to the shareholders to not to redeem. The remaining funds will be released to us and can be used to pay all or a portion of the purchase price of the business or businesses with which our initial business combination occurs or for general corporate purposes, including payment of principal or interest on indebtedness incurred in connection with our initial business combination, to fund the purchases of other companies, or for working capital. The underwriters will not be entitled to any interest accrued on the deferred underwriting discounts and commissions.